FDA issued a warning letter to Lima & Pergher Industria e Comercio S/A for CGMP violations.
On August 25, 2016, FDA issued a warning letter to Lima & Pergher Industria e Comercio S/A following an inspection of the company’s facility in Uberlandia, Brazil, performed from February 29–March 3, 2016. The company was cited for current good manufacturing practice (CGMP) violations specific to ensuring quality in their products. FDA placed the company on Import Alert 66-40 on July 15, 2016.
FDA inspectors found that the company had not established adequate written procedures for its quality control unit, including the review and approval of production and control records and the handling and review of out-of-specification investigations. The company also failed to perform microbiological testing on each lot of finished product.
Components, drug product containers, or closures were released that did not meet appropriate specifications for identity, strength, quality, and purity. Inspectors also found that expiration dates on products were not supported by stability data.
FDA stated in the letter that the company’s response to the FDA 483 was inadequate. “Although you committed to establish written procedures for quality unit responsibilities and stability studies, your response lacked details. You did not include a retrospective review of CGMP deficiencies on the quality of your products already in United States distribution,” the agency stated. FDA recommends the company hire a consultant to assist in meeting CGMP requirements.
Source: FDA
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.